Celularity (NASDAQ:CELU) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Celularity (NASDAQ:CELU) to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings upgraded shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Celularity Stock Performance

NASDAQ CELU traded down $0.05 during trading hours on Friday, reaching $0.63. The company’s stock had a trading volume of 138,784 shares, compared to its average volume of 174,813. The stock has a market cap of $20.45 million, a PE ratio of -0.37 and a beta of 0.88. Celularity has a fifty-two week low of $0.56 and a fifty-two week high of $2.55. The company’s 50-day moving average is $1.18 and its two-hundred day moving average is $1.06.

Celularity (NASDAQ:CELU) last posted its earnings results on Tuesday, October 20th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $5.43 million for the quarter.

Institutional Trading of Celularity

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. bought a new stake in Celularity, Inc. (NASDAQ:CELU) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises approximately 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th biggest position. C V Starr & Co. Inc. owned about 2.64% of Celularity as of its most recent filing with the Securities and Exchange Commission. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease. The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.